Johnson & Johnson UPTRAVI — Percent Change (as a percent) decreased by 44.1% to 24.3% in Q3 2025 compared to the prior quarter. Year-over-year, this metric declined by 50.1%, from 48.7% to 24.3%. This decline may warrant attention — for this metric, higher values are generally preferred.
A positive percentage indicates sales growth, while a negative percentage indicates a contraction in revenue, helping to identify trends in product maturity or market saturation.
This metric measures the period-over-period percentage growth or decline in net sales for the UPTRAVI product line. It p...
Comparable to year-over-year or sequential growth rate metrics reported for individual pharmaceutical products by industry peers.
jnj_segment_uptravi_percent_change_as_a_percent| Q2 '21 | Q3 '21 | Q4 '21 | Q2 '22 | Q3 '22 | Q4 '22 | Q2 '23 | Q3 '23 | Q1 '24 | Q2 '24 | Q3 '24 | Q1 '25 | Q2 '25 | Q3 '25 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Value | 66.9% | 71.9% | 66.7% | 31.3% | 32.5% | 28.5% | 27.8% | 70.5% | 88.9% | 34.5% | 48.7% | 2.9% | 43.5% | 24.3% |
| QoQ Change | — | +7.5% | -7.2% | -53.1% | +3.8% | -12.3% | -2.5% | +153.6% | +26.1% | -61.2% | +41.2% | -94.0% | >999% | -44.1% |
| YoY Change | — | — | — | -53.2% | -54.8% | -57.3% | -11.2% | +116.9% | — | +24.1% | -30.9% | -96.7% | +26.1% | -50.1% |
We use cookies for analytics. See our Privacy and Cookie Policy.